Mike Yee joined UBS as Global Head of Biotechnology Equity Research in December 2025 and has been working in Healthcare Equity Research on Wall Street for more than 25 years including over 20 years covering the Biotechnology sector. He was previously a Managing Director covering Biotechnology at Jefferies since 2017 and before that at RBC Capital Markets. He is a top-ranked analyst in the Institutional Investor poll and has been consistently ranked Top 2-3 for Large-Cap and Small/Mid Cap biotechnology categories for many years. Michael Yee is also a frequent TV guest on financial news and media outlets. Prior to RBC, Michael previously worked in equity research at Deutsche Bank in the Life Sciences sector. Michael received a BA in Molecular Cell Biology from the University of California, Berkeley, and an MBA from UC Berkeley's Haas School of Business.